Moderna Delivers Surprise Profit Amid Covid Vaccine Sales Dip
Thursday, 22 February 2024, 11:34
Moderna's Surprising Quarterly Profit
Moderna, a leading pharmaceutical company, has managed to achieve a profitable quarter despite facing a decline in sales of its Covid vaccines.
Strong Financial Guidance for 2024
- Moderna reiterated its full-year 2024 sales guidance of roughly $4 billion.
This unexpected financial performance showcases Moderna's resilience and adaptability in a challenging market environment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.